




<b>Name</b>	Suzanne Trudel	
<b>Current Position</b>	Professor	
<b>Country</b>	Canada	
<b>Major Field</b>	Hematology	

## Educational Background

- 1990 - 1994 MD, University of Toronto, Toronto, Ontario, Canada
- 1988 - 1991 MSc, Biochemistry, University of Toronto, Toronto, Ontario, Canada
- 1984 - 1988 BSc, Biochemistry, McGill University, Montreal, Quebec, Canada

## Postgraduate, Research and Specialty Training

- 2000 - 2003 Research Fellow, Division of Hematology, Weill Medical College of Cornell, New York City, New York, United States
- 1997 - 1999 Resident, Division of Hematology, University of Toronto, Toronto, Ontario, Canada
- 1994 - 1997 Resident, Division of General Internal Medicine, University of Toronto, Toronto, Ontario, Canada

## Professional Experience

- 2019 - present Clinician Scientist, Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- 2023 Jul - present Associate Professor, Medicine, University of Toronto, Toronto, Ontario, Canada
- 2006 - present Associate Member, Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
- 2003 Apr - present Staff Physician, Division of Hematology, University Health Network/Princess Margaret Cancer Centre, Toronto, M5G 2M9, Ontario, Canada

## Other Experience and Professional Memberships

### American Society of Hematology (ASH)

- 2007 - 2010 **Member**, Ad Hoc Scientific Committee (Plasma Cell Biology)

### International Myeloma Foundation

- 2018 - present **Member**, International Myeloma Working Group

### Multiple Myeloma Research Consortium, (MMRC)

- 2005 - present **Member**, Project Review Committee *is to select and prioritize the MMRC pre-clinical and clinical research effort.*



2013 - 2018 **Member**, Steering Committee

National Cancer Institute (NCI)

2021 - present **Special Expert Member**, Myeloma Steering Committee

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)

2006 - present **Member**, Hematology Sub-Committee on Correlative Sciences, Canada.

## Main Scientific Publications

1. Cipkar C, Chen C and Trudel S. Antibodies and bispecifics for multiple myeloma: effective effector therapy. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):1630172. PMID 2022000334. **Senior Responsible Author.**
2. Croucher DC, Richards LM, Tsofack SP, Waller D, Li Z, Wei EN, Huang XF, Chesi M, Bergsagel PL, Sebag M, Pugh TJ, **Trudel S**. Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression. Nat Commun. 2021 Nov 3;12(1):6322. PMID: 34732728. Impact Factor 14.92 (Trainee publication, PhD candidate). **Senior Responsible Author.**
3. Liyasova M, McDonald Z, Taylor P, Gorospe K, Xu X, Yao C, Liu Q, Yang L, Atenafu EG, Piza G, Ma B, Reece D, **Trudel S**. A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM). Clin Cancer Res. 2021 Sep 15;27(18):5028-5037. PMID: 34210683. Impact Factor 12.53. **Senior Responsible Author.**
4. Longo J, Smirnov P, Li Z, Branchard E, van Leeuwen JE, Licht JD, Haibe-Kains B, Andrews DW, Keats JJ, Pugh TJ, **Trudel S**, Penn LZ. The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma. Leukemia. 2021 Mar 1;35(3):796-808. Impact Factor 11.53. **Co-Senior Responsible Author.**
5. Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ, MAIA Trial Investigators. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019;380(22):2104-2115. PMID Number: 31141632. Impact Factor 74.699. **Coauthor or Collaborator.**
6. **Trudel S**, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson LD Jr, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018 Dec 1;19(12):1641-1653. PMID: 30442502. Impact Factor 36.4. **Principal Author.**
7. Kis O, Kaedbey R, Chow S, Danesh A, Dowar M, Li T, Li Z, Liu J, Mansour M, Masih-Khan E, Zhang T, Bratman SV, Oza AM, Kamel-Reid S, **Trudel S**, Pugh TJ. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. Nat Commun. 2017 May 11;8:15086. PMID 28492226. Impact Factor 12.35 (Trainee publication, Clinical Fellow). **Co-Senior Responsible Author.**
8. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, **Trudel S**, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR. Initial genome sequencing and



---

analysis of multiple myeloma. *Nature*. 2011 Mar 24;471(7339):467-72. PMID: 21430775. Impact Factor 36.1. **Coauthor or Collaborator.**

9. Chen CI, Bergsagel PL, Paul H, Xu W, Lau A, Dave N, Kukreti V, Wei E, Leung-Hagesteijn C, Li ZH, Brandwein J, Pantoja M, Johnston J, Gibson S, Hernandez T, Spaner D, **Trudel S**. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. *J Clin Oncol*. 2011 Mar 20;29(9):1175-81. PMID: 21189385. Impact Factor 18.97. **Senior Responsible Author.**
  10. **Trudel S**, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. *Blood*. 2007 Jun 15;109(12):5430-8. PMID: 17332241. Impact Factor 10.896. **Senior Responsible Author.**
  11. **Trudel S**, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. *Blood* 2005 Apr 1;105(7):2941-8. PMID:15598814. Impact Factor 10.131. **Principal Author.**
  12. **Trudel S**, Ely S, Farooqi Y, Affer M, Robbani DF, Chesi M, Bergsagel PL. Inhibition of fibroblast growth factor differentiation and apoptosis in t(4;14) myeloma. *Blood*. 2004 May 1;103(9):3521-8. PMID: 14715624. **Principal Author.**
-